Intralesional administration of interferon alpha (INF-A) is a new approach in haemangiomas treatment that we electively apply to our patients. The aim of this study is to report the beneficial results of this new kind of therapy. Thirty-two patients with severe haemangiomas, 19 females and 13 males, were treated at our department from January 2000 to December 2004. All patients received INF-A intralesionally at a dose of 1–3 MIU/m2 of body surface once a day for the first week, and then once a week until completion of therapy. Reduction was evaluated after clinical and radiological measurement before, during and after completion of therapy and was graded as complete (>80%), significant (50–80%), medial (20–50%) and no response (<19%). Mean duration of therapy was 8 weeks (2 months). Most patients had not received prior therapy. Complete regression was noticed in 18 patients, satisfactory in 8 patients, minimal in 4 and no response in 2 patients. Minimal complications such as flu-like malaise with fever were reported by 23 patients at the beginning of therapy, but it was resolved easily by paracetamol administration. Complications such as haemorrhage or allergic reaction during administration or neurological symptoms were not reported or noticed. Intralesional administration of interferon A can be considered as a safe option for the management of massive or life-threatening haemangiomas as it requires reduced duration of treatment; hence this option results in reduced financial cost, is well tolerated by patients and is free of major complications.
Haemangioma Interferon A Intralesional administration
This is a preview of subscription content, log in to check access.
Silverman RA (1991) Hemangiomas and vascular malformations. Ped Clin North Am 38:811–834Google Scholar
Weber TR, Connors RH, Tracy TF, Bailey PV (1990) Complex hemangiomas of infants and children: individual management in 22 cases. Arch Surg 125:1017–1021PubMedGoogle Scholar
Chen MT, Yeong EW, Horug SY (2000) Intralesional corticosteroids therapy in proliferative head and neck hemangiomas: a review of 155 cases. J Ped Surg 35(3):420–423CrossRefGoogle Scholar
Moore J, Lee M, Gazzon M et al (2001) Effective therapy of a vascular tumor of infancy with vincristine. J Ped Surg 36(8):1273–1276CrossRefGoogle Scholar
Marler JJ, Rubin JB, Trede NS et al (2002) Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics 109(2):E37PubMedCrossRefGoogle Scholar
Miller SH, Smith RL, Schochut SJ (1976) Compression treatment of hemangiomas. Plast Surg 58:573–579Google Scholar
Fledelius HC, Illum N, Jensen H, Prause JU (2001) Interferon-alfa treatment of facial infantile haemangiomas: with emphasis on the sight-threatening varieties. A clinical series. Acta Ophthalmol Scand 79(4):370–373PubMedCrossRefGoogle Scholar
Grimal I, Duveau E, Enjolras O, Verret JL, Ginies JL (2000) Effectiveness and dangers of interferon- alpha in the treatment of severe hemangiomas in infants. Arch Pediatr 7(2):163–167PubMedCrossRefGoogle Scholar
Schiavetti A, De Pasquale MD, Di Salvo S, Ventriglia F, Clerico A (2003) Recombinant interferon alfa 2a in hepatic hemangiomatosis with congestive heart failure: a case report. Pediatr Hematol Oncol 20(2):161–165PubMedCrossRefGoogle Scholar
Dubois J, Hershon L, Carmant L, Belanger S, Leclerc JM, David M (1999) Toxicity profile of interferon alfa-2b in children: a prospective evaluation. J Pediatr 135(6):782–785PubMedCrossRefGoogle Scholar
Garmendia G, Miranda N, Borosso S, Longchong M, Martinez E, Ferrero J, Porrero P, Lopez-Saura P (2001) Regression of infancy hemangiomas with recombinant IFN- alpha 2b. J Interferon Cytokine Res 21(1):31–38PubMedCrossRefGoogle Scholar
Tamayo L, Ortiz DM, Orozco-Covarrubias L, Duran-McKinster C, Mora MA, Avila E, Teixeira F, Ruiz-Maldonado R (1997) Therapeutic efficacy of interferon alfa-2b in infants with life threatening giant hemangiomas. Arch Dermatol 133(12):1567–1571PubMedCrossRefGoogle Scholar